Navigation Links
Visikol Launches OpenLiver™ 3D Cell Culture Models to Accelerate Drug Discovery
Date:1/20/2019

As the leader in 3D cell culture characterization and analysis, Visikol is now expanding their service offering through the introduction of its own liver 3D cell culture models. In an effort to build a consensus in the market, Visikol will be open-sourcing all of its models, protocols and validation criteria so that any researcher can replicate these models for their internal research efforts.

Recently, researchers have begun to make the shift from 2D to 3D cell culture models, as 3D models have been shown in various applications to better recapitulate the complex in vivo microenvironment. Particularly in liver contexts, 3D models derived from human hepatocytes have been shown to more accurately mimic liver functionalities, bile canalicular networks, and expression of key drug transporters relevant to human metabolism when compared to 2D cultures or even in vivo mouse models.

Despite the increasing implementation of 3D models to study drug induced liver injury (DILI) and other liver disease phenotypes (i.e. steatosis, inflammation, fibrosis), proprietary practices of private companies and many labs have stymied the generation of consensus around appropriate models for particular research questions. This lack of consensus often lends to the implementation of needlessly expensive and complex models (e.g. a primary hepatocyte and non-parenchymal cell co-culture) to address simplistic questions that could be answered with more inexpensive biology (e.g. HepG2 spheroids). Alternatively, models lacking specific physiological functionalities are occasionally implemented inappropriately to answer complex questions, misleading the interpretations of results.

As a leader in 3D cell culture assays, Visikol has decided to address this need for consensus by introducing its own suite of open source 3D cell culture models, offered under the OpenLiver™ 3D cell culture model platform. Through this endeavor, Visikol will openly provide all protocols, material procurement information, validation criteria, and assay guidance, in an effort to start building consensus in the field and to allow for the more rapid adoption of these models. “The reason we launched our OpenLiver™ initiative is that we recognized that there is little consensus in the 3D cell culture space about which model is ideal for specific research questions, and many researchers needlessly use expensive and complex biology whereas other researchers attempt to use inadequate biology to address their research question” explained Visikol Chief Science Officer Dr. Tom Villani.

Through a partnership with Biopredic, Visikol has launched its OpenLiver™ initiative with the OpenLiver™ 3D HepaRG™ NP model, which is a co-culture of HepaRG™ cells and a non-parenchymal cell population. While this model does not use primary human hepatocytes, it is highly reproducible, since it leverages HepaRG OpenLiver™ 3D HepaRG™ NP hepatoma cells, which allows for sufficient in vivo relevancy for many research questions at a lower price point relative to primary human hepatocytes. “One of the main goals of our OpenLiver™ 3D HepaRG™ NP initiative is to not only launch models that we can use in our services, but also to educate researchers about how best to answer their research question and which models are most suitable for different questions” described Visikol Director of In Vitro Studies Dr. Erin Edwards.

Visikol has begun to offer its OpenLiver™ 3D HepaRG / NPC model for use within its assay services and has priced the model so that it is affordable for any research group.

About Visikol
Visikol is a CRO focused on advanced drug discovery that is leading the field of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

Read the full story at https://www.prweb.com/releases/visikol_launches_openliver_3d_cell_culture_models_to_accelerate_drug_discovery/prweb16027993.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Visikol Co-Founder Michael Johnson named to 2017 Forbes 30 Under 30 List
2. Visikol Hits Key Milestone, Recognized by Forbes for Passion & Innovation
3. Visikol Appoints Pharmaceutical Industry Leader, Stewart Hunt, as Director of US Sales
4. Come Visit Visikol at SLAS to Learn About 3D Cell Culture Assays and Models
5. Biopredic International and Visikol Partner on Liver 3D Cell Culture Liver Development
6. Earth Week: American U. launches William K. Reilly Fund for Environmental Governance & Leadership
7. University of Maryland Medical Center launches genetic-testing program for cardiac patients
8. Frontiers launches new open-access journal in Bioengineering and Biotechnology
9. Frontiers launches new open-access journal in physics
10. Elsevier launches new open access journal: Translational Proteomics
11. Elsevier launches open access journal: GeoResJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2019)... (PRWEB) , ... January 31, 2019 , ... ... SCOPE Summit , geared toward clinical operations executives and focusing on all facets ... importance of effective project management, portfolio management, resource management, patient engagement, and more. ...
(Date:2/2/2019)... SAN FRANCISCO (PRWEB) , ... February 01, 2019 ... ... granted ISO 15189 Accreditation for Clinical Testing Laboratories by A2LA, which establishes requirements ... to an international standard. The laboratory is already CLIA-licensed as well as College ...
(Date:1/25/2019)... ... January 24, 2019 , ... ... of its 2019 Association Industry Survey. The report indicates membership growth in some ... mid-November to early December 2018, received responses from over 500 association professionals across ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... Texas (PRWEB) , ... January 29, 2019 , ... ... and Marketing with Lifecycle since 2016. In his position as Director of Sales ... science tools and services supplier across multiple industries the company supports. During this ...
(Date:1/30/2019)... SAN FRANCISCO (PRWEB) , ... January 30, 2019 ... ... the leader in microbial genomics, has awarded microbiome research support in study design, ... A&T State University led by Dr. Marc D. Cook, PhD, to study the ...
(Date:1/24/2019)... (PRWEB) , ... January 22, 2019 , ... ... since each trial has its own set of assumptions, and RFP creation and ... so evaluating bids is like comparing apples to oranges. These challenges can ultimately ...
(Date:1/20/2019)... ... ... The American Society of Gene & Cell Therapy (ASGCT) is proud to announce ... 2019. Designed by ASGCT committee volunteers in coordination with patient advocacy groups, the new ... the status and promise of gene and cell therapies. , Gene Therapy 101 ...
Breaking Biology Technology: